{"prompt": "['Informed consent is a process that is initiated prior to the individual consent to participate in', \"the study and continues throughout the individual's participation. Extensive discussion of\", 'risks and possible benefits of participation will be provided to the participants and their', 'families. Consent forms will be IRB approved and the participant will be asked to read and', 'review the document. The investigator will explain the research study to the participant and', 'answer any questions that may arise. All participants will receive a verbal explanation in', 'terms suited to their comprehension of the purposes, procedures, and potential risks of the', 'study and of their rights as research participants. Participants will have the opportunity to', 'carefully review the written consent form and ask questions prior to signing.', 'The participants should have the opportunity to discuss the study with their surrogates or', 'think about it prior to agreeing to participate. The participant will sign the informed consent', 'document prior to any procedures being done specifically for the study. The participants may', 'withdraw consent at any time throughout the course of the trial. A copy of the informed', 'consent document will be given to the participants for their records. The rights and welfare of', 'the participants will be protected by emphasizing to them that the quality of their medical', 'care will not be adversely affected if they decline to participate in this study.', '10.3.3 Institutional Review Board/Ethics Committee', 'The protocol, informed consent form, recruitment materials, and all participant materials will', 'be submitted to the IRB for review and approval. Approval of both the protocol and the', 'consent form must be obtained before any participant is enrolled. Any amendment to the', 'protocol will require review and approval by the IRB before the changes are implemented to', 'the study. All changes to the consent form will be IRB approved; a determination will be', 'made regarding whether previously consented participants need to be re-consented.', '10.3.4 Participant and data confidentiality', 'Participant confidentiality is strictly held in trust by the participating investigators, their staff,', 'and the sponsor(s) and their agents. This confidentiality is extended to cover testing of', 'biological samples and genetic tests in addition to the clinical information relating to', 'participants. Therefore, the study protocol, documentation, data, and all other information', 'generated will be held in strict confidence. No information concerning the study or the data', 'will be released to any unauthorized third party without prior written approval of the', 'sponsor.', 'The study monitor, other authorized representatives of the sponsor, representatives of the IRB', 'or pharmaceutical company supplying study product may inspect all documents and records', 'required to be maintained by the investigator, including but not limited to, medical records', '(office, clinic, or hospital) and pharmacy records for the participants in this study. The', 'clinical study site will permit access to such records.', \"The study participant's contact information will be securely stored at each clinical site for\", 'internal use during the study. At the end of the study, all records will continue to be kept in a', 'secure location for as long a period as dictated by local IRB and Institutional regulations.', '69']['Study participant research data, which is for purposes of statistical analysis and scientific', \"reporting, will be transmitted to and stored. This will not include the participant's contact or\", 'identifying information. Rather, individual participants and their research data will be', 'identified by a unique study identification number. The study data entry and study', 'management systems used by clinical sites and research staff will be secured and password', 'protected. At the end of the study, all study databases will be de-identified and archived.', '10.3.5 Research use of stored samples, specimens, or data', 'Samples and data collected under this protocol may be used to study RCC. Access to stored', 'samples will be limited to IRB-approved investigators. Samples and data will be stored using', 'codes assigned by the investigators or their designees. Data will be kept in password-', 'protected computers. Only investigators will have access to the samples and data.', 'All stored samples will be maintained in the laboratory to which it was sent initially for', 'analysis. Study participants who request destruction of samples will be notified of', 'compliance with such request and all supporting details will be maintained for tracking.', '10.4 Conditions for Modifying the Protocol', 'Protocol modifications (including protocol amendments) may be made and will be prepared,', 'reviewed, and approved by representatives of the principal investigator. Protocol', 'modifications or amendments must be reviewed and approved by Merk prior to', 'implementation.', 'All protocol modifications must be submitted to the IRB/EC for information and approval in', 'accordance with local requirements and to regulatory agencies if required. Approval must be', 'obtained before any changes can be implemented, except for changes necessary to eliminate', 'an immediate hazard to study subjects or those that involve only logistical or administrative', 'aspects of the trial (e.g. change in monitor or change of telephone number).', '10.5 Conditions for Terminating the Study', 'At any time, the study may be terminated by the investigator, the IRB, or by Merk Should', 'this be necessary, Merk and the investigator will arrange the procedures on an individual', 'study basis after review and consultation. In terminating the study, Merk and the', \"investigator will ensure that adequate consideration is given to the protection of the subjects'\", 'interests. Upon study termination, the investigator(s) shall cease enrolling subjects into the', 'study, and shall discontinue conduct of the study as soon as is medically practical.', '11.0 REFERENCES', '1.', 'Dindo, D., N. Demartines, and P.A. Clavien, Classification of surgical complications:', 'a new proposal with evaluation in a cohort of 6336 patients and results of a survey.', 'Ann Surg, 2004. 240(2): p. 205-13.', '70']\n\n###\n\n", "completion": "END"}